{"contentid": 488222, "importid": NaN, "name": "Amzell signs agreement with Amring Pharmaceuticals", "introduction": "Dutch specialist development pharma, Amzell has signed a license and development agreement with Amring Pharmaceuticals, a subsidiary of SEVER Life, for the commercial rights to one of its leading clinical-stage candidates.", "content": "<p>Dutch specialist development pharma, Amzell has signed a license and development agreement with Amring Pharmaceuticals, a subsidiary of SEVER Life, for the commercial rights to one of its leading clinical-stage candidates. &nbsp;</p>\n<p>Under the agreement, Amzell will complete the full clinical development of the product, and Amring will take on the commercialization. Amring will also be investing an undisclosed amount into the product&rsquo;s clinical development and the Food and Drug Administration approval process.</p>\n<p>Amzell chief executive Dario Carrara commented: &ldquo;We are very excited to be working with Amring to bring this product to the market and into extensive clinical use where it can meet critical patient needs. This program is one of our top priorities. We are moving rapidly into the advanced phase of our clinical trial program.&rdquo;</p>\n<p>Daniel Carbery, president and CEO of Amring, added: &ldquo;With the completion of this agreement and the acquisition of broad commercial rights, Amring is rapidly expanding its position as an important leader in bringing critical and affordable treatments for patients. This agreement will significantly expand our commercial presence in the USA and several regions globally. We believe that this brings long term value to patients and customers in our target markets.&rdquo;</p>\n<p>Just last week, Amzell said it has acquired Bazell Pharma, a high-end clinical development and R&amp;D laboratory facility based in Allschwil, Switzerland, to help to accelerate its development pipeline of late-stage novel drug candidates.</p>\n<p>Amzell specializes in developing well-characterized active substances utilizing its innovative drug delivery technology platforms. Its innovative platform drug delivery technologies provide effective drug delivery, increased efficacy, and improved safety and compliance. Amzell currently has a number of novel candidates in clinical development, and the recently acquired a high-end clinical laboratory facility based in Allschwil, Switzerland, to help to accelerate its growing development pipeline.</p>", "date": "2021-03-31 16:15:00", "meta_title": "Amzell signs agreement with Amring Pharmaceuticals", "meta_keywords": "Amzell, Amring Pharmaceuticals, License, Development, Agreement", "meta_description": "Amzell signs agreement with Amring Pharmaceuticals", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-31 16:12:45", "updated": "2021-03-31 17:52:06", "access": NaN, "url": "https://www.thepharmaletter.com/article/amzell-signs-agreement-with-amring-pharmaceuticals", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "amring_pharmaceuticals_large.png", "image2id": "amring_pharmaceuticals_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": NaN, "topic_tag": "Deals, Licensing, One to Watch Companies, Research", "geography_tag": "The Netherlands", "company_tag": "Amring Pharmaceuticals, Amzell", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-31 16:15:00"}